These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35487094)

  • 1. Clinical performance of DNA and RNA based HPV tests for test of cure (TOC) post treatment for cervical intraepithelial neoplasia (CIN) - a retrospective study.
    Bhatia R; Graham C; Elasifer H; Asodaria P; Moncur S; Wilson A; Palmer T; Cuschieri K
    J Clin Virol; 2022 Jun; 150-151():105165. PubMed ID: 35487094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H).
    Cubie HA; Canham M; Moore C; Pedraza J; Graham C; Cuschieri K
    J Clin Pathol; 2014 Jun; 67(6):458-63. PubMed ID: 24436334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
    Zhang H; Varma KR; Han M; Matsko J; Zhao C
    Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.
    Iftner T; Becker S; Neis KJ; Castanon A; Iftner A; Holz B; Staebler A; Henes M; Rall K; Haedicke J; von Weyhern CH; Clad A; Brucker S; Sasieni P
    J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical performance of a human papillomavirus messenger RNA test (Aptima HPV Assay) on residual material from archived 3-year-old PreservCyt samples with low-grade squamous intraepithelial lesion.
    Waldstrøm M; Ornskov D
    Arch Pathol Lab Med; 2011 Aug; 135(8):1052-6. PubMed ID: 21809999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
    Oštrbenk Valenčak A; Šterbenc A; Seme K; Poljak M
    J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31666369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
    Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
    BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions.
    Virtanen E; Kalliala I; Dyba T; Nieminen P; Auvinen E
    Acta Obstet Gynecol Scand; 2017 Jan; 96(1):61-68. PubMed ID: 27858961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.
    Iftner T; Neis KJ; Castanon A; Landy R; Holz B; Woll-Herrmann A; Iftner A; Staebler A; Wallwiener D; Hann von Weyhern C; Neis F; Haedicke-Jarboui J; Martus P; Brucker S; Henes M; Sasieni P
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aptima HPV messenger RNA testing and histopathologic follow-up in women with HSIL cytology: A study emphasizing additional review of HPV-negative cases.
    Li A; Li J; Austin RM; Wang T; Ashman D; Zhang H; Matsko J; Zhao C
    Cancer Cytopathol; 2021 Aug; 129(8):622-631. PubMed ID: 33764649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study.
    Reid JL; Wright TC; Stoler MH; Cuzick J; Castle PE; Dockter J; Getman D; Giachetti C
    Am J Clin Pathol; 2015 Sep; 144(3):473-83. PubMed ID: 26276778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stepwise algorithm combining HPV high-risk DNA-based assays and RNA-based assay for high grade CIN in women with abnormal smears referred to colposcopy.
    Halfon P; Benmoura D; Agostini A; Khiri H; Pénaranda G; Martineau A; Blanc B
    Cancer Biomark; 2010; 7(3):133-9. PubMed ID: 21263189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.
    Luttmer R; Berkhof J; Dijkstra MG; van Kemenade FJ; Snijders PJ; Heideman DA; Meijer CJ
    J Clin Virol; 2015 Jun; 67():59-66. PubMed ID: 25959161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.
    Arbyn M; Simon M; de Sanjosé S; Clarke MA; Poljak M; Rezhake R; Berkhof J; Nyaga V; Gultekin M; Canfell K; Wentzensen N
    Lancet Oncol; 2022 Jul; 23(7):950-960. PubMed ID: 35709810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.
    Verdoodt F; Szarewski A; Halfon P; Cuschieri K; Arbyn M
    Cancer Cytopathol; 2013 Dec; 121(12):675-87. PubMed ID: 23881840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical performance of the aptima HPV assay in 4196 women with positive high-risk HPV and ASC-US cytology: A large women hospital experience.
    Wang T; Pradhan D; Zhang H; Matsko J; Zhao C
    Diagn Cytopathol; 2021 Jan; 49(1):5-10. PubMed ID: 32857920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test.
    Poljak M; Kovanda A; Kocjan BJ; Seme K; Jancar N; Vrtacnik-Bokal E
    Acta Dermatovenerol Alp Pannonica Adriat; 2009 Sep; 18(3):94-103. PubMed ID: 19784522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.